Global Cardiology Academy

Welcome to Global
Cardiology Academy

Enhance your cardiology practice with CME and
tools focused on heart health management.

MinuteCE®
The Ambulatory HFrEF Blind Spot: Proactively Reducing CV Mortality Risk Despite Optimized GDMT
0.75 credits 5 episodes
- Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
- Javed Butler, MD
- Prof. Dr. Johann Bauersachs
0.75 credits 5 episodes
GDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
GDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
CME/CE
GDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
0.25 credits
- Prof. Dr. Johann Bauersachs
- Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
0.25 credits
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
Global Neurology Academy
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
- Mike Sharma, MD, MSc, FRCPC
ATTRibute-CM Findings on Acoramidis and Cumulative CV Events
ATTRibute-CM Findings on Acoramidis and Cumulative CV Events
On the Frontlines of ATTR-CM
ATTRibute-CM Findings on Acoramidis and Cumulative CV Events
- Ryan Quigley
- Ahmad Masri, MD, MS
Redefining ATTR Treatment: Key Mechanisms and Emerging Data
Redefining ATTR Treatment: Key Mechanisms and Emerging Data
Heart Matters
Redefining ATTR Treatment: Key Mechanisms and Emerging Data
- Ahmad Masri, MD, MS
ATTRibute-CM Trial Updates: Long-Term Outcomes With Acoramidis
ATTRibute-CM Trial Updates: Long-Term Outcomes With Acoramidis
On the Frontlines of ATTR-CM
ATTRibute-CM Trial Updates: Long-Term Outcomes With Acoramidis
- Ryan Quigley
- Kevin Alexander, MD
Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
Heart Matters
Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
- Kevin Alexander
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
CME/CE
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
0.50 credits
- Richard E. Pratley, MD
- David Cherney, MD, PhD
- prof. Hiddo Heerspink
0.50 credits

Programs

Can AI Transform How We Diagnose ATTR-CM?
Can AI Transform How We Diagnose ATTR-CM?
On the Frontlines of ATTR-CM
Can AI Transform How We Diagnose ATTR-CM?
- Ryan Quigley
- Frederick Ruberg, MD
Safety, Clinical Integration, and the Emerging Fifth Pillar in HF Practice
Safety, Clinical Integration, and the Emerging Fifth Pillar in HF Practice
MinuteCE®
Safety, Clinical Integration, and the Emerging Fifth Pillar in HF Practice
0.75 program credits
- Prof. Dr. Johann Bauersachs
- Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
0.75 program credits
Missing the Window in Ambulatory Patients With HFrEF on GDMT: Strategies for CV Risk Reduction
Missing the Window in Ambulatory Patients With HFrEF on GDMT: Strategies for CV Risk Reduction
CME/CE
Missing the Window in Ambulatory Patients With HFrEF on GDMT: Strategies for CV Risk Reduction
0.25 credits
- Stephen J. Greene, MD, FACC, FHFSA
- Gianluigi Savarese, MD
0.25 credits
Treating ATTR-CM Early: A Shift From Reactive to Strategic Care
Treating ATTR-CM Early: A Shift From Reactive to Strategic Care
Heart Matters
Treating ATTR-CM Early: A Shift From Reactive to Strategic Care
- Quan Bui, MD
Exploring Tafamidis Survival Data in Elderly Patients with ATTR-CM
Exploring Tafamidis Survival Data in Elderly Patients with ATTR-CM
AudioAbstracts
Exploring Tafamidis Survival Data in Elderly Patients with ATTR-CM
- Hallie Blevins, PhD
ATTR-CM Trials Revisited: A Broader View of Treatment Benefit
ATTR-CM Trials Revisited: A Broader View of Treatment Benefit
Heart Matters
ATTR-CM Trials Revisited: A Broader View of Treatment Benefit
Understanding Diagnostic Gaps Among Medicare Patients with ATTRwt-CM
Understanding Diagnostic Gaps Among Medicare Patients with ATTRwt-CM
Heart Matters
Understanding Diagnostic Gaps Among Medicare Patients with ATTRwt-CM
From HCM to ATTR-CM: Rethinking Unexplained Hypertrophy
From HCM to ATTR-CM: Rethinking Unexplained Hypertrophy
AudioAbstracts
From HCM to ATTR-CM: Rethinking Unexplained Hypertrophy
- Hallie Blevins, PhD

Clinical Practice

Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Global Neurology Academy
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
- Ashkan Shoamanesh, MD
Patient Voices in ATTR-CM: Driving Change in Diagnosis, Referral, and Support
Patient Voices in ATTR-CM: Driving Change in Diagnosis, Referral, and Support
On the Frontlines of ATTR-CM
Patient Voices in ATTR-CM: Driving Change in Diagnosis, Referral, and Support
- Ryan Quigley
- Quan Bui, MD
Earlier Action, Lasting Impact: Closing the LDL-C Gap in Patients Without a Prior MACE
Earlier Action, Lasting Impact: Closing the LDL-C Gap in Patients Without a Prior MACE
CME/CE
Earlier Action, Lasting Impact: Closing the LDL-C Gap in Patients Without a Prior MACE
0.25 credits
- Erin Bohula, MD, DPhil
- Lawrence Leiter
0.25 credits
Closing Gaps in ASCVD Prevention: Lipid Management Insights from AHA 2025
Closing Gaps in ASCVD Prevention: Lipid Management Insights from AHA 2025
Heart Matters
Closing Gaps in ASCVD Prevention: Lipid Management Insights from AHA 2025
- Laurence Sperling, MD
- Eugenia Gianos, MD
Highlights of the Latest Hypertension Guidelines
Highlights of the Latest Hypertension Guidelines
Cardiology
Highlights of the Latest Hypertension Guidelines
- Clyde W. Yancy, MD
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Heart Matters
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
- Jun-ichi Abe
Targeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control
Targeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control
Heart Matters
Targeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control
The Fifth Pillar? Closing the Gap in HFrEF
The Fifth Pillar? Closing the Gap in HFrEF
CME/CE
The Fifth Pillar? Closing the Gap in HFrEF
0.50 credits
- Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
- Javed Butler, MD
- Stephen J. Greene, MD, FACC, FHFSA
0.50 credits

CME

GDMT Is Working Fine, Why Add More Therapies? The Clinical Rationale for Layering Therapies in Patients with HFrEF
GDMT Is Working Fine, Why Add More Therapies? The Clinical Rationale for Layering Therapies in Patients with HFrEF
MinuteCE®
GDMT Is Working Fine, Why Add More Therapies? The Clinical Rationale for Layering Therapies in Patients with HFrEF
0.75 program credits
0.75 program credits
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
CME/CE
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
0.25 credits
- Scott Solomon, MD
0.25 credits
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
CME/CE
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
0.50 credits
- prof. Hiddo Heerspink
- Peter Rossing, MD, DMSc
- Paola Fioretto, MD
0.50 credits
Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD
Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD
CME/CE
Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD
0.25 credits
- Rajiv Agarwal, MBBS, MD, FASN, BRCU
- Prof. Dr. Francesc Xavier Cos Claramunt
0.25 credits
MinuteCE®
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
1.00 credit 9 episodes
- James Burton, DM, FRCP
- Leonie Kraft, MD
- Lucio Manenti, MD, PhD
- Emilio Sanchez, MD, PhD
1.00 credit 9 episodes
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
CME/CE Broadcast Replay
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
0.50 credits
- Prof. Ulrich Laufs
- Pam R. Taub, MD, FACC, FASPC
- Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
- Christie Ballantyne, MD
0.50 credits
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
CME/CE
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
0.25 credits
- Riccardo Maria Inciardi, MD, PhD
0.25 credits
Unmasking Hidden Risk: The Role of Lp(a) in Cardiovascular Risk Assessment
Unmasking Hidden Risk: The Role of Lp(a) in Cardiovascular Risk Assessment
MinuteCE®
Unmasking Hidden Risk: The Role of Lp(a) in Cardiovascular Risk Assessment
1.00 program credit
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
- Rishi Wadhera, MD, MPP, Mphil
1.00 program credit